Ethiodized Oil

Melanoma

National Institutes of Health Clinical Center (CC)Phase 1Dormant

C

37/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 65/ 100

Competitive context

329 Active assets in the Melanoma cohort.

Asset / Sponsor	Phase	Rating
DACARBAZINE Suzhou BlueHorse Therapeutics Co., Ltd.	Phase 3	BB
Cyclophosphamide Primmune Therapeutics, Inc.	Phase 4	BB
Nivolumab Bristol-Myers Squibb	Phase 4	BB
Epirubicin Primmune Therapeutics, Inc.	Phase 4	BB
Pembrolizumab Biocon Biologics UK PLC	Phase 4	BB

View all 50 →

Same molecule, other indications

Ethiodized Oil is also rated in:

hepatocellular carcinomaDormant

BB

Indicative ·

70 / 100

Colon Cancer Liver MetastasisDormant

BB

Indicative ·

66 / 100

Neoplastic Cells, CirculatingDormant

BB

Indicative ·

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.